Last 12 months
Inside the activity.
0 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2018 Filed Jun 7, 2018 20:21 UTC |
Richard RonaldDirector
|
SaleCommon Stock | 7,342 | $53.00 | $389,126.00 |
DisclosureSEC source: 0001140361-18-027686 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 16:27 UTC |
Hauer Jerome MDirector
|
SaleCommon Stock | 8,375 | $52.16 | $436,876.01 |
DisclosureSEC source: 0001140361-18-027687 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,588 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.63, inclusive. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 21:07 UTC |
Abdun-Nabi DanielDirector · Chief Executive Officer
|
SaleCommon Stock | 15,785 | $52.11 | $822,614.75 |
DisclosureSEC source: 0001140361-18-027713 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,343 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.83 to $52.66. inclusive. Read SEC document |
| May 24, 2018 Filed May 24, 2018 20:34 UTC |
Zoon Kathryn CDirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025519 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,638 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 24, 2018 18:25 UTC |
Bailey SueDirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025558 · doc1.xml · nonDerivative · entry 1 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 24, 2018 18:07 UTC |
Hauer Jerome MDirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025551 · doc1.xml · nonDerivative · entry 1 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,963 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 24, 2018 18:30 UTC |
JOULWAN GEORGE ADirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025562 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,272 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 24, 2018 20:33 UTC |
SULLIVAN LOUIS WDirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025518 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,972 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. F3 · balance_after: The amount of securities beneficially owned includes the correction of a mathematical error reported in a Form 4 filed on May 26, 2017. Read SEC document |
| May 24, 2018 Filed May 24, 2018 22:29 UTC |
Harsanyi ZsoltDirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025560 · doc1.xml · nonDerivative · entry 1 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,972 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 24, 2018 22:28 UTC |
Richard RonaldDirector
|
GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025559 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,305 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:16 UTC |
Zoon Kathryn CDirector
|
SaleCommon Stock | 1,377 | $51.15 | $70,433.55 |
DisclosureSEC source: 0001140361-18-025992 · doc1.xml · nonDerivative · entry 1 Zoon Kathryn C · CIK 0001685720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,261 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Zoon. Read SEC document |
| May 08, 2018 Filed May 10, 2018 16:39 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 237 | $48.33 | $11,454.21 |
DisclosureSEC source: 0001140361-18-022813 · doc1.xml · nonDerivative · entry 1 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,834 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC |
LINDAHL RICHARD SEVP, Chief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 19,963 | $48.33 Strike: $48.33 | $964,811.79 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · derivative · entry 4 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,963 Underlying: Common Stock · 19,963 shares Expires 2025-05-07 F4 · derivative.exercise_date: Vests in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC |
LINDAHL RICHARD SEVP, Chief Financial Officer
|
GrantCommon Stock | 4,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · nonDerivative · entry 3 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,534 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC |
LINDAHL RICHARD SEVP, Chief Financial Officer
|
GrantCommon Stock | 1,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · nonDerivative · entry 2 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,543 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:56 UTC |
LINDAHL RICHARD SEVP, Chief Financial Officer
|
GrantCommon Stock | 4,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022841 · doc1.xml · nonDerivative · entry 1 LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,992 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:37 UTC |
Kramer RobertPresident and COO
|
GrantEmployee Stock Option · Derivative | 2,586 | $48.33 Strike: $48.33 | $124,981.38 |
DisclosureSEC source: 0001140361-18-022810 · doc1.xml · derivative · entry 4 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586 Underlying: Common Stock · 2,586 shares Expires 2025-05-07 F5 · derivative.exercise_date: Vests on May 7, 2019; May 7, 2020 and May 7, 2021 in equal annual installments. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:37 UTC |
Kramer RobertPresident and COO
|
GrantCommon Stock | 646 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022810 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,172 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:37 UTC |
Kramer RobertPresident and COO
|
GrantCommon Stock | 647 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022810 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,526 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:49 UTC |
Richard RonaldDirector
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,893 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001140361-18-019061 · doc1.xml · derivative · entry 3 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:49 UTC |
Richard RonaldDirector
|
SaleCommon Stock | 7,893 | $55.00 | $434,115.00 |
DisclosureSEC source: 0001140361-18-019061 · doc1.xml · nonDerivative · entry 2 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,410 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 20:49 UTC |
Richard RonaldDirector
|
Exercise / conversionCommon Stock | 7,893 | $13.37 | $105,529.41 |
DisclosureSEC source: 0001140361-18-019061 · doc1.xml · nonDerivative · entry 1 Richard Ronald · CIK 0001380177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:57 UTC |
Havey AdamEVP, Business Operations
|
SaleCommon Stock | 5,842 | $52.82 | $308,574.44 |
DisclosureSEC source: 0001140361-18-013317 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,914 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.50 to $53.16, inclusive. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:23 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestrictive Stock Units · Derivative | 13,237 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-007329 · doc4.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,598 Underlying: Common Stock · 13,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F4 · derivative.expiration_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:23 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 3,224 | $51.84 | $167,132.16 |
DisclosureSEC source: 0000899243-18-007329 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554,993 Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:23 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 13,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007329 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:57 UTC |
Havey AdamEVP, Business Operations
|
Tax withholdingCommon Stock | 974 | $51.84 | $50,492.16 |
DisclosureSEC source: 0001140361-18-013317 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,756 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:18 UTC |
Kramer RobertEVP, Administration and CFO
|
Tax withholdingCommon Stock | 1,727 | $51.84 | $89,527.68 |
DisclosureSEC source: 0001140361-18-013320 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,879 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:53 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Tax withholdingCommon Stock | 7,825 | $51.84 | $405,648.00 |
DisclosureSEC source: 0001140361-18-013315 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,128 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:24 UTC |
Havey AdamEVP, Business Operations
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-18-012878 · doc1.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F3 · derivative.exercise_date: The option vested in three equal installments in March 2012, March 2013 and March 2014. Each option represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:24 UTC |
Havey AdamEVP, Business Operations
|
Tax withholdingCommon Stock | 2,843 | $50.43 | $143,372.49 |
DisclosureSEC source: 0001140361-18-012878 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,730 F1 · shares: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting persons exercise price for the reported stock option exercise. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:24 UTC |
Havey AdamEVP, Business Operations
|
Exercise / conversionCommon Stock | 6,573 | $22.03 | $144,803.19 |
DisclosureSEC source: 0001140361-18-012878 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 1, 2018 22:03 UTC |
Havey AdamEVP, Business Operations
|
SaleCommon Stock | 1,898 | $49.50 | $93,951.00 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F5 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 17:05 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 540 | $49.97 | $26,983.80 |
DisclosureSEC source: 0001140361-18-011289 · doc1.xml · nonDerivative · entry 4 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,071 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestrictive Stock Units · Derivative | 9,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 10 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,835 Underlying: Common Stock · 9,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F7 · derivative.expiration_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 2,368 | $49.97 | $118,328.96 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,980 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 9,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,547,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:04 UTC |
Kramer RobertEVP, Administration and CFO
|
Tax withholdingCommon Stock | 1,545 | $49.97 | $77,203.65 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,606 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:03 UTC |
Havey AdamEVP, Business Operations
|
Tax withholdingCommon Stock | 811 | $49.97 | $40,525.67 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,898 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:01 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Tax withholdingCommon Stock | 6,599 | $49.97 | $329,752.03 |
DisclosureSEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,953 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 17:05 UTC |
Strei KatherineEVP, Chief HR Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 16,116 | $49.64 Strike: $49.64 | $799,998.24 |
DisclosureSEC source: 0001140361-18-011289 · doc1.xml · derivative · entry 5 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,116 Underlying: Common Stock · 16,116 shares Expires 2025-02-26 F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 17:05 UTC |
Strei KatherineEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 387 | $49.64 | $19,210.68 |
DisclosureSEC source: 0001140361-18-011289 · doc1.xml · nonDerivative · entry 3 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,611 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 17:05 UTC |
Strei KatherineEVP, Chief HR Officer
|
GrantCommon Stock | 4,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011289 · doc1.xml · nonDerivative · entry 2 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,998 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 17:05 UTC |
Strei KatherineEVP, Chief HR Officer
|
GrantCommon Stock | 4,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011289 · doc1.xml · nonDerivative · entry 1 Strei Katherine · CIK 0001709639 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,969 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestrictive Stock Units · Derivative | 9,794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 9 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,558 Underlying: Common Stock · 9,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F6 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 38,577 | $0.00 Strike: $49.64 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,577 Underlying: Common Stock · 38,577 shares Expires 2025-02-26 F5 · derivative.exercise_date: On February 27, 2018, Mr. El-Hibri was granted 38,577 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
GrantRestrictive Stock Units · Derivative | 19,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,352 Underlying: Common Stock · 19,288 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 2,385 | $49.64 | $118,391.40 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,625 Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 9,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:04 UTC |
Kramer RobertEVP, Administration and CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 23,670 | $49.64 Strike: $49.64 | $1,174,978.80 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,670 Underlying: Common Stock · 23,670 shares Expires 2025-02-26 F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.